Anru Wang1, Xueqin Yan2, Cai Zhang3, Caiqi Du4, Wenjun Long5, Di Zhan6, Xiaoping Luo7. 1. A Wang, Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. X Yan, Pediatrics, Boai Hospital of Zhongshan, Zhongshan, China. 3. C Zhang, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 4. C Du, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 5. W Long, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 6. D Zhan, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 7. X Luo, Pediatrics, Tongji Hospital, Wuhan, 430030, China xpluo@tjh.tjmu.edu.cn.
Abstract
BACKGROUND: Fibroblast growth factor 1 (FGF1) can regulate glucose and lipid metabolism in obese mice. Serum FGF1 have increased in type 2 diabetes mellitus adults and correlated with BMI. This study aimed to indicate conventional weight loss effects on FGF1 in obese children and adolescents. MATERIALS AND METHODS: Clinical and metabolic parameters of 88 lean and obese individuals (ages 5-15 years) and 39 obese individuals followed with 6 months of lifestyle intervention were collected. Serum FGF1 levels were detected through enzyme-linked immunosorbent assays. RESULTS: FGF1 levels were increased in obese individuals. Serum FGF1 levels were significantly correlated with BMI and waist circumferences (r = 0.377, P = 0.012; r = 0.301, P = 0.047, respectively). Multivariate stepwise linear regress analyses showed that FGF1 levels were significantly correlated with HbA1c and HOMA-IR (β = 0.371, P = 0.008; β = 0.323, P = 0.021, respectively). Weight loss (2.3 ± 0.1 kg) was accompanied by a significant reduction of circulating FGF1 levels (7.2 ± 0.4 pg/ml). Changes in FGF1 were significantly correlated with changes in fasting glucose, HOMA-IR and low-density lipoprotein-cholesterol (β = 0.277, P = 0.020; β = 0.474, P < 0.001; β = 0.320, P = 0.008, respectively). CONCLUSION: FGF1 was related to increased risk of insulin resistance in obese children and adolescents. Serum FGF1 reduced after weight loss in obese individuals and was associated with the improvement of insulin resistance. Changes in serum FGF1 was more correlated with insulin resistance than changes in obesity per se.
BACKGROUND: Fibroblast growth factor 1 (FGF1) can regulate glucose and lipid metabolism in obese mice. Serum FGF1 have increased in type 2 diabetes mellitus adults and correlated with BMI. This study aimed to indicate conventional weight loss effects on FGF1 in obese children and adolescents. MATERIALS AND METHODS: Clinical and metabolic parameters of 88 lean and obese individuals (ages 5-15 years) and 39 obese individuals followed with 6 months of lifestyle intervention were collected. Serum FGF1 levels were detected through enzyme-linked immunosorbent assays. RESULTS: FGF1 levels were increased in obese individuals. Serum FGF1 levels were significantly correlated with BMI and waist circumferences (r = 0.377, P = 0.012; r = 0.301, P = 0.047, respectively). Multivariate stepwise linear regress analyses showed that FGF1 levels were significantly correlated with HbA1c and HOMA-IR (β = 0.371, P = 0.008; β = 0.323, P = 0.021, respectively). Weight loss (2.3 ± 0.1 kg) was accompanied by a significant reduction of circulating FGF1 levels (7.2 ± 0.4 pg/ml). Changes in FGF1 were significantly correlated with changes in fasting glucose, HOMA-IR and low-density lipoprotein-cholesterol (β = 0.277, P = 0.020; β = 0.474, P < 0.001; β = 0.320, P = 0.008, respectively). CONCLUSION: FGF1 was related to increased risk of insulin resistance in obese children and adolescents. Serum FGF1 reduced after weight loss in obese individuals and was associated with the improvement of insulin resistance. Changes in serum FGF1 was more correlated with insulin resistance than changes in obesity per se.
Authors: Louise Hutley; Wenda Shurety; Felicity Newell; Ross McGeary; Nicole Pelton; Jennifer Grant; Adrian Herington; Donald Cameron; Jon Whitehead; Johannes Prins Journal: Diabetes Date: 2004-12 Impact factor: 9.461
Authors: Johan W Jonker; Jae Myoung Suh; Annette R Atkins; Maryam Ahmadian; Pingping Li; Jamie Whyte; Mingxiao He; Henry Juguilon; Yun-Qiang Yin; Colin T Phillips; Ruth T Yu; Jerrold M Olefsky; Robert R Henry; Michael Downes; Ronald M Evans Journal: Nature Date: 2012-05-17 Impact factor: 49.962
Authors: Vera J M Nies; Gencer Sancar; Weilin Liu; Tim van Zutphen; Dicky Struik; Ruth T Yu; Annette R Atkins; Ronald M Evans; Johan W Jonker; Michael Robert Downes Journal: Front Endocrinol (Lausanne) Date: 2016-01-19 Impact factor: 5.555
Authors: Jarrad M Scarlett; Jennifer M Rojas; Miles E Matsen; Karl J Kaiyala; Darko Stefanovski; Richard N Bergman; Hong T Nguyen; Mauricio D Dorfman; Louise Lantier; David H Wasserman; Zaman Mirzadeh; Terry G Unterman; Gregory J Morton; Michael W Schwartz Journal: Nat Med Date: 2016-05-23 Impact factor: 53.440